

わが国の硬膜移植後Creutzfeldt-Jakob病の特徴: 海外例との比較

研究分担者: 金沢大学大学院医学系研究科 脳老化・神経病態学(神経内科学) 浜口 毅

1. わが国と海外の硬膜移植後CJDの比較

2. 疾患別の硬膜移植時年齢の比較

	Japan	Other countries	<i>p</i>		Japan	Other countries																								
Pateints	142	48			years, mean ± S.D.	years, mean ± S.D.																								
Sex, female (%)	58.5%	42.2%	n.s.	Tumor	43.8 ± 13.8 (n=62)	31.7 ± 16.3 (n=25)																								
Age at dura mater graft (year)	43.1 ± 15.1	31.1 ± 15.0	<i>p</i> <0.001	Vascular diseases	40.2 ± 17.7 (n=41)	35.7 ± 6.1 (n=3)																								
Age at CJD onset (year)	55.7 ± 14.9	41.9 ± 15.4	<i>p</i> <0.001	Trauma	24.5 ± 17.2 (n=6)	27.8 ± 15.1 (n=6)																								
Incubation period (year)	12.1 ± 5.8	10.8 ± 6.0	n.s.	Diseases of cranial nerves	50.2 ± 9.4 (n=26)	50 (n=1)																								
Rate of using Lyodura [®] , % (n)	100% (127)	91.2% (31)	<i>p</i> <0.01	Others	44.3 ± 10.4 (n=6)	29.1 ± 14.0 (n=13)																								
Diseases for dura mater graft, % (n)				<h3>3. わが国と海外のdCJD症例の硬膜移植を受けた原因疾患のうち腫瘍の病型別の頻度の比較</h3> <table border="1"> <thead> <tr> <th></th> <th>Japan</th> <th>Other countries</th> </tr> </thead> <tbody> <tr> <td>Meningioma</td> <td>30 (48.4%)</td> <td>8 (32.0%)</td> </tr> <tr> <td>Acoustic neurinoma</td> <td>17 (27.4%)</td> <td>3 (12.0%)</td> </tr> <tr> <td>Glioma</td> <td>2 (3.2%)</td> <td>8 (32.0%)</td> </tr> <tr> <td>Ependymoma</td> <td>2 (3.2%)</td> <td>0 (0%)</td> </tr> <tr> <td>Heamangioblastoma</td> <td>2 (3.2%)</td> <td>2 (8.0%)</td> </tr> <tr> <td>Spinal cord tumor</td> <td>2 (3.2%)</td> <td>1 (4.0%)</td> </tr> <tr> <td>Others</td> <td>7 (11.3%)</td> <td>3 (12.0%)</td> </tr> </tbody> </table>				Japan	Other countries	Meningioma	30 (48.4%)	8 (32.0%)	Acoustic neurinoma	17 (27.4%)	3 (12.0%)	Glioma	2 (3.2%)	8 (32.0%)	Ependymoma	2 (3.2%)	0 (0%)	Heamangioblastoma	2 (3.2%)	2 (8.0%)	Spinal cord tumor	2 (3.2%)	1 (4.0%)	Others	7 (11.3%)	3 (12.0%)
	Japan	Other countries																												
Meningioma	30 (48.4%)	8 (32.0%)																												
Acoustic neurinoma	17 (27.4%)	3 (12.0%)																												
Glioma	2 (3.2%)	8 (32.0%)																												
Ependymoma	2 (3.2%)	0 (0%)																												
Heamangioblastoma	2 (3.2%)	2 (8.0%)																												
Spinal cord tumor	2 (3.2%)	1 (4.0%)																												
Others	7 (11.3%)	3 (12.0%)																												
Tumor	43.7% (62)	52.1% (25)	<i>p</i> <0.001																											
Vascular diseases	28.9% (41)	6.3% (3)																												
Trauma	4.2% (6)	12.5% (6)																												
Diseases of cranial nerves	18.3% (26)	2.1% (1)																												
Others	4.9% (7)	27.1% (13)																												
Codon 129 polymorphism, % (n)																														
Met/Met	96.6% (57)	83.3% (25)	<i>p</i> <0.05																											
Met/Val	3.4% (2)	6.7% (2)																												
Val/Val	0% (0)	10.0% (3)																												
Pathology, % (n)																														
Non-plaque	54.8% (17)	78.9% (15)	n.s.																											
Plaque	45.2% (14)	21.1% (4)																												

n.s.; not significant, CJD; Creutzfeldt-Jakob disease, Met: methionine, Val: valine

解説

1. 硬膜移植を受けた年齢は、日本の症例の方が有意に高齢であった
2. 潜伏期間は、日本の症例と海外の症例の間に差は無かった。
3. 硬膜移植を受けた原因疾患の割合は、日本と海外で有意に異なった。
4. 日本では、プリオン蛋白遺伝子コドン129多型がmethionine homozygoteの症例が有意に多かった。